Related by context. All words. (Click for frequent words.) 72 Lung Cancer Screening 70 Digital Mammographic Imaging 68 Aggressive Reduction 67 Screening Trial 66 Intervention Trial GAIT 66 Lung Screening 66 Prostate Lung Colorectal 65 Screening Trial DMIST 64 Prostate Cancer Prevention 64 Clinical Antipsychotic Trials 63 Carotid Revascularization Endarterectomy vs. 63 Ovarian Cancer Screening 63 CT Colonography Trial 62 Preclinical Study 62 Cholesterol Levels SPARCL 62 Acute Myocardial Infarction 62 number NCT# ClinicalTrials.gov 61 Ovarian PLCO Cancer 61 PLCO 61 Oral Fingolimod 61 First Patient Enrolled 61 Cancer Incidence Mortality 61 CAMMS# 61 DMIST 60 Trial PCPT 60 Intervention Effectiveness 60 Glucosamine Chondroitin Arthritis 60 Heart Assn 60 Patient Registry 60 European Randomized Study 60 Pooled Analysis 60 CURRENT OASIS 7 60 Prostate AdenoCarcinoma Treatment 60 multicenter randomized clinical 60 ELCAP 60 Randomized Double Blind 60 ENESTnd 59 Combination Treatment 59 ONTARGET 59 ExTRACT TIMI 59 Randomized Study 59 Edge STudy 59 Celecoxib APC trial 59 Intervention Effectiveness CATIE 59 Cardiac Allograft Rejection 59 ACRIN 59 Phase III AFFIRM 59 Randomized Phase II 59 Carotid Endarterectomy 59 ACUITY trial 59 CARE HF 58 Early Lung Cancer 58 CHAMPION PCI 58 ASTEROID 58 ST Segment Elevation 58 Prospective Multicenter 58 PRoFESS 58 HORIZONS AMI 58 BRIM3 58 Multicenter Randomized 58 multicenter clinical 58 ASCO GU 58 Renal Cell Carcinoma 58 Platelet Inhibition 58 Vaccine Protects Against 58 Lancet Oncology journal 58 HORIZONS AMI trial 58 Artery Disease 58 CT Colonography 58 Ischemic Stroke 58 Prospective Randomized 58 AVERROES 58 Severe Sepsis 58 STICH trial 58 Stenting Trial CREST 58 Hormone Receptor Positive 58 Deforolimus 58 PERSEUS 58 THAT ARE DIFFICULT TO 58 Coronary Artery Calcium 58 Glucosamine chondroitin Arthritis 58 National Emphysema Treatment 58 Prostate Cancer Screening 58 RE LY 58 Randomized Phase III 57 Phase Ib Clinical Trial 57 Stenting Trial 57 Proves Effective 57 CLARITY TIMI 57 Breast Density 57 Pre Exposure Prophylaxis 57 EVEREST II 57 Severe Asthma 57 Coronary Revascularization 57 Venous Thromboembolism 57 Recurrent Breast Cancer 57 placebo controlled clinical 57 ARBITER 6 57 Neurologic Disorders 57 CT Angiography 57 HPTN 57 Antitumor Activity 57 multicenter randomized controlled 57 Combination REOLYSIN R 57 Sipuleucel T 57 Heart Failure Trial 57 randomized controlled clinical 57 Controlled Trial 57 BCIRG 57 Acute Decompensated Heart Failure 57 Meta Analysis 57 Clinical Outcome 57 ENDEAVOR IV 57 AACR #st Annual Meeting 57 Oncotype DX TM 57 International Verapamil SR 57 Trandolapril 57 Invasive Breast Cancer 57 Prostate Cancer Treatment 57 II Clinical Trial 57 Localized Prostate Cancer 57 Gastric Cancer 57 Clinical Trial Results 57 SPIRIT FIRST 57 Phase 2b Clinical Trial 57 Phase Ib II 57 Alpha Tocopherol Beta Carotene 57 Prostate Cancer Patients 57 Double Blind Placebo 57 Nymox NX 57 AVOREN 57 Myocardial Infarction 57 Ovarian Cancer Patients 57 Multicenter Study 57 Intervention Trial 56 ACCOMPLISH 56 Carotid Stenting 56 Metastatic Prostate Cancer 56 ERSPC 56 Hepatocellular Carcinoma 56 RE LY ® 56 LUX Lung 56 Intracranial Aneurysms 56 Computed Tomographic 56 Observational Study 56 Nicotine Vaccine 56 Evaluation WISE 56 CTRC AACR San Antonio 56 Renal Cell Carcinoma RCC 56 Surgical Treatment 56 Prolongs Survival 56 Pre RELAX AHF 56 Cardiotoxicity 56 Gynecologic Oncology Group 56 Randomized Double blind 56 AACR IASLC Joint 56 Stent Thrombosis 56 AACR San Antonio 56 Atherosclerosis MESA 56 Multicenter Automatic Defibrillator Implantation 56 Cardiac Resynchronization 56 Aortic Stenosis 56 BOLDER II 56 Pivotal Clinical Trial 56 riociguat 56 Diabetic Macular Edema 56 CATIE AD 56 Molecular Origins 56 Prevalence Worldwide 56 Aortic Dissection 56 Randomized Trials 56 Relapsed Multiple Myeloma 56 Registry NOPR 56 Colorectal Cancers 56 Confirms Efficacy 56 www.cancerconsultants.com 56 Non Alcoholic Steatohepatitis 56 recurrent glioma 56 Stomach Cancer 56 HeFT 56 Genes Predict 56 Prostate Screening 56 Breast Cancer Detection 56 Multi Ethnic Study 56 By JENNIFER LEARN 56 AA Amyloidosis 56 Study Evaluating 56 Phase 2b Study 56 Clinical Trial Evaluating 56 Phase Ib clinical 56 Randomized Evaluation 56 registrational Phase 56 Phase 2b Trial 56 CALGB # [001] 56 Adjuvant Chemotherapy 55 Acute Ischemic Stroke 55 SPARCL 55 SEER database 55 Controlled Study 55 Hepatocellular Carcinoma HCC 55 Breast Carcinoma 55 Lung Cancer Survival 55 Outpatient Setting 55 Nonalcoholic Fatty Liver Disease 55 Brain Scans 55 HCV SPRINT 55 Advanced Melanoma 55 EchoCRT 55 UroVysion 55 Clostridium difficile Infection 55 Therapeutic Efficacy 55 Disease Progression 55 Heart Failure Therapies 55 phase IIIb 55 Nicotine Addiction 55 NSABP B 55 Phase III Trial 55 Phase 1b clinical trials 55 Topline Results 55 Placebo Controlled 55 SCD HeFT 55 Dialysis Outcomes 55 phase IIb study 55 relapsed MM 55 Acute Stroke 55 Uterine Cancer 55 Hormone Refractory Prostate Cancer 55 Health Initiative WHI 55 ORAL Solo 55 ACCORD Lipid 55 ThermoDox ® clinical 55 STRIDE PD 55 Breast Cancer Recurrence 55 Lymph Nodes 55 Cervista HPV HR 55 Thromboembolism 55 SPIRIT IV 55 Cardiovascular Outcomes 55 VADT 55 Cognitive Function 55 Treatment Shows Promise 55 randomized multicenter trial 55 AIM HIGH 55 Bone Marrow Transplants 55 Smoking Linked 55 Critical Limb Ischemia CLI 55 evaluating mipomersen 55 Male Infertility 55 Vaccine Prevents 55 Reduced Risk 55 Cancer Prevention ATBC 55 Neoadjuvant Chemotherapy 55 Malignant Melanoma 55 Venous Thrombosis 55 STEP BD 55 Truvada tablets 55 Shows Efficacy 55 Prostate Cancer Survival 55 Vaccine Adjuvant 55 Improves Survival 55 Clinical Trial Data 55 Visceral Fat 55 Women Ischemia Syndrome 55 substudy 55 multicenter placebo controlled 55 Septic Shock 55 Wisconsin Sleep Cohort 55 #rd Annual CTRC 55 Acute Heart Failure 55 Treatment Reduces 55 Heart Failure Patients 55 Pivotal Trial 55 phase IIb trial 55 Microbicide 55 Test Detects 55 iPrEx 55 Hepatitis C Infection 55 Statin Drugs 55 MEND CABG 55 Autologous Stem Cell Transplantation 55 Drug Prevents 55 Randomized Clinical Trial 55 Non Melanoma Skin 55 Inflammatory Markers 55 Coronary Artery Bypass Graft 55 Placebo Controlled Trial 54 rosuvastatin #mg 54 Childhood Asthma 54 Heart Transplant Recipients 54 Ciccarone Preventive Cardiology 54 Prostate Cancer Outcomes 54 Chronic Liver Disease 54 EUS FNA 54 FOLOTYN ® 54 JAK Inhibitor 54 OncoVex 54 Asthma Intervention 54 REGARDS 54 prospective observational cohort 54 Preclinical Data 54 Rosuvastatin 54 Demonstrates Efficacy 54 Sequencing Systems 54 Hormone Therapy 54 Node Positive 54 prospective multicenter 54 Lung Injury 54 Phase III Clinical Trial 54 Atherosclerosis Risk 54 Genitourinary Cancers Symposium 54 HER2 Positive 54 Epidemiologic studies 54 Knee Osteoarthritis 54 Cancer Incidence 54 Drug Combo 54 Skin Lesions 54 PROactive study 54 Gene Mutations 54 Bayer HealthCare Onyx Pharmaceuticals 54 CYT# potent vascular disrupting 54 Guidelines Issued 54 GOUT 54 Refractory Angina 54 Asthma Treatment 54 Catheter Ablation 54 dose escalation clinical 54 ACS NSQIP 54 Postmenopausal 54 SABCS 54 ISEL 54 BARI 2D 54 ST Elevation Myocardial 54 Hydroxyurea 54 Thrombolysis 54 Study ADCS 54 Myocardial Infarction Study 54 journal Hepatology 54 Endocrine Society #st 54 Ridaforolimus 54 Diabetes Complications 54 multicenter prospective 54 Lipid Lowering Treatment 54 Testosterone Patch 54 Phase 2a Trial 54 Treating Chronic 54 Lung Cancer Risk 54 Drug Shows Promise 54 Intelligence Network NCIN 54 Breast Cancer Mortality 54 AVN# Phase 54 Study Validates 54 Phase 1b Clinical Trial 54 PreCISe 54 ECASS 54 Cervical Dysplasia 54 blinded randomized placebo controlled 54 Randomized Controlled 54 Mortality Risk 54 REACH Registry 54 NABTT 54 Safinamide 54 Effective Treatments 54 Degarelix 54 Periodontal Disease 54 Randomized trials 54 Investigator Initiated 54 Immunomedics Announces 54 Phase IIB 54 Calcium Intake 54 Screening Mammography 54 Study Demonstrates 54 Radiofrequency Ablation 54 Ranolazine 54 Stem Cell Treatment 54 Coronary Disease 54 Non Invasive Treatment 54 RE LY trial 54 Improves Outcomes 54 Lung Cancer Drug 54 Breast Cancers 54 Genetic Markers 54 Lowers Risk 54 ALLHAT 54 Pulmonary Arterial Hypertension 54 Phase III ThermoDox 54 #F FDG PET 54 oral FTY# 54 Successfully Treated 54 Universal Flu Vaccine 54 Renal Tumors 53 MGd 53 MADIT CRT 53 Discoveries Tomorrow 53 EXPLORE Xa 53 ANCHOR trial 53 Subgroup Analysis 53 Biomarker Study 53 Illicit Drug Use 53 Anti Tumor Activity 53 Treat Parkinson Disease 53 Newly Diagnosed Multiple Myeloma 53 Lung Cancer Trial 53 Pirfenidone 53 Pharmacodynamic 53 Lung Cancer Patients 53 EURIDIS 53 NCCTG N# 53 #-# Full Text 53 Neoadjuvant 53 Solid Tumors 53 Improve Survival 53 Darapladib 53 Genes Identified 53 CAPRISA 53 Carcinomas 53 Naive Patients 53 Thoracic Oncology Program 53 B Cell Lymphoma 53 Communities ARIC study 53 Group RTOG 53 Colorectal Adenomas 53 BR.# 53 Minimally Invasive Treatment 53 PERSEUS clinical program 53 Acta Scandinavica 53 Insulin Resistance Atherosclerosis 53 Sentinel node biopsy 53 Phase #b/#a clinical 53 Chronic Heart Failure 53 Multicenter 53 Therapy Shows Promise 53 HDAC Inhibitor 53 Advanced Renal Cell 53 Antiplatelet Therapy 53 Survival Benefit 53 Improved Survival 53 Hepatotoxicity 53 Inhaled Corticosteroids 53 Overactive Bladder 53 Novel Treatments 53 Breast Cancer Treatment 53 See CLINICAL PHARMACOLOGY 53 Left Ventricular Dysfunction 53 ONTARGET R 53 Dual Antiplatelet Therapy 53 Epeius Biotechnologies Corporation 53 Nesiritide 53 Acute Liver Failure 53 Guidelines Recommend 53 Infarct 53 Reduces Mortality 53 Adjuvant Therapy 53 Subgroup analysis 53 Echocardiographic 53 Inflammatory Disease 53 By SCOTT RASMUSSEN 53 iPrEx study 53 Systematic Review 53 MERLIN TIMI 53 RE MODEL 53 Recurrent Stroke 53 Unresectable 53 flurpiridaz F 53 Randomized Controlled Trials 53 Pharmacokinetic Study 53 dual endothelin receptor antagonist 53 Clinical Evaluation 53 REALITY Trial 53 Catheterization 53 WHEL 53 Multiethnic Study 53 Patient Outcomes 53 Survival Rates 53 Hospital Acquired Pneumonia 53 Cancer Institute www.cancer.gov 53 CARDIA 53 PCI ExTRACT TIMI 53 prospective randomized multicenter 53 Antifungals 53 Gene Therapy Trial 53 AIR2 Trial 53 Tesmilifene 53 SWOG 53 Therapeutic Targets 53 Chronic Bronchitis 53 Watchful Waiting 53 CAPRIE 53 Kidney Failure 53 Lupus Drug 53 prospective nonrandomized 53 Aromatase Inhibitors 53 Acute Coronary Syndromes 53 NATRECOR ® 53 Resistant Hypertension 53 Effectively Treats 53 Placebo Controlled Study 53 prospective observational 53 placebo controlled Phase III 53 Pivotal Phase III 53 Dr. Claudia Henschke 53 Afatinib 53 Rectal Cancer 53 Diabetes Interventions 53 Cancer Biomarkers 53 Renal Cancer 53 endometriosis ovarian cysts 53 Anti Tumor 53 CABG Surgery 53 Gene Linked 53 Tanespimycin 53 Autoimmune Disease 53 Analytical Tool 53 Nutrition Examination 53 #:#-# [033] 53 MEK Inhibitor 53 Aggressive Prostate Cancer 53 Genes Linked 53 Bronchiectasis 53 Cervical Cancer Vaccine 53 Gynecological Cancer 53 LungAlert TM 52 Adenoma 52 Multicenter Phase 52 Sleep Disturbances 52 Risk Stratification 52 Tiotropium 52 Castration Resistant Prostate Cancer 52 Long Term Efficacy 52 #F FDG PET CT 52 cardiac computed tomography 52 Brentuximab Vedotin SGN 52 TAXUS IV 52 ASCO Breast Cancer 52 angiography CCTA 52 RECORD1 52 Treating Depression 52 Squamous 52 Slow Progression 52 bazedoxifene conjugated estrogens 52 Cancer Genetic Markers 52 Hematological Cancers 52 undergone radical prostatectomy 52 Complications Trial 52 IMPROVE HF 52 Genetic Variations 52 Clinical Trials Update 52 Cochrane Systematic Review 52 Arch Neurol 52 Investigational Treatment 52 TMC# C# 52 Statistically Significant 52 ENDEAVOR III 52 Neuroendocrine Tumor 52 Phase III Pivotal Trial 52 Initiates Phase III 52 Sequenced Treatment Alternatives 52 Left Ventricular Hypertrophy 52 Cholesterol Drug 52 multicenter phase 52 Fungal Infections 52 IASLC 52 Obesity Linked 52 Stop Hypertension DASH 52 Enzastaurin 52 Acute myocardial infarction 52 Long Lesion 52 BY WILLA J. 52 familial amyloidotic polyneuropathy FAP 52 Shows Promise Against 52 FDG PET 52 Therapeutic Arthritis 52 CALGB # [002] 52 #th Interscience Conference 52 Often Misdiagnosed 52 OLYMPIA registry 52 Denufosol 52 selenium supplementation 52 mg BID dose 52 MADIT II 52 Study Casts Doubt 52 PICSO ® 52 Premature Births 52 subanalysis 52 Clinical Efficacy 52 Erectile Dysfunction Drug 52 Helps Diagnose 52 Glatiramer Acetate 52 multicentre randomized controlled 52 Hepatitis C Antiviral 52 Antidepressant Use 52 Improve Diagnosis 52 Prostate Cancer Symposium 52 Blood Cancers 52 ADA Scientific Sessions 52 PSMA ADC 52 recurrent glioblastoma multiforme 52 Muscle Function 52 intensive statin therapy 52 MERIT ES 52 National Oncologic PET 52 PROLARIS 52 Therapeutic Effects 52 Subtypes 52 Recurrent Prostate Cancer 52 PD2i R 52 Phase IIIb 52 Cognitive Deficits 52 Anti Clotting Drug 52 Baltimore Longitudinal Study 52 NCI Cancer 52 Renal Function 52 Late Breaker 52 First Patient Dosed 52 PRESEPT 52 Hematological 52 NO# [002] 52 Multicenter AIDS 52 multicenter trials 52 TNFerade TM 52 PERISCOPE 52 Leukemias 52 HIV HCV coinfected 52 Alzheimer Disease Neuroimaging Initiative 52 prostate cancer CaP 52 TAXUS ATLAS 52 Aflibercept 52 STRATEGY FOR AN OPEN 52 Birth Defects Prevention 52 Anticancer Drug 52 methylation markers 52 Patients Treated With 52 Long Term Outcomes 52 Predict Risk 52 phase IIb clinical 52 Treatment Outcomes 52 BRAF mutated 52 Bone Fractures 52 Laryngeal Cancer 52 Clinical Guideline 52 Functional magnetic resonance 52 Syncria R 52 EORTC 52 genomewide association study 52 Adult Stem Cell Therapy 52 Protein Linked 52 Vaccine Trials 52 Peripheral Blood 52 Enlarged Prostate 52 Investigational Drug 52 simplex virus 52 Thyroid Cancer 52 Randomised 52 BREVAGen ™ 52 Decompensated Heart Failure 52 F FDG PET 52 beta carotene supplementation 52 Bladder Cancer 52 Rotavirus Vaccine 52 Chemoprevention 52 Postmenopausal Women 52 Cholesterol Levels 52 Study AREDS 52 CALGB 52 deCode genetics 52 PROactive Study 52 Tumor Response 52 Adjuvant Breast Cancer 52 Arthritis Drugs 52 Completes Enrollment 52 BMC Musculoskeletal Disorders 52 #st Annual Meeting 52 Uterine Fibroid Embolization 52 Blinatumomab 52 Epilepsy Drug 52 Pharmacokinetic PK 52 Chronic Inflammation 52 Hyperlipidemia 52 Antipsychotic Drug 52 Radiation Therapy Oncology 52 Kidney Transplant Patients 52 Seasonal Allergic Rhinitis 52 Pivotal Study 52 Neuroepidemiology 52 NDA Submission 52 TG MV 52 Cytopathology 52 FDA Approves Drug 52 NOMID 52 prospective multicentre 52 Randomized Trial 52 Autoimmune Diseases 52 ATACAND 52 Rheumatology Annual 52 Metastatic Melanoma 52 Toxicity Testing 52 p# biomarker 52 Squamous Cell 52 prospective multicenter study 52 Anticancer Activity 52 Stem Cell Transplants 52 ticagrelor Brilinta 52 miRview ™ mets 52 Genetic Predisposition 52 Serious Infections 52 Lupus Nephritis 52 carotid artery stenting CAS 52 Inflammatory Bowel Diseases 52 Weight Loss Supplement 52 Demonstrates Sustained 52 Heart Failure Treatment 52 Adjuvant Treatment 52 Imetelstat 52 deCODE AF TM 52 ZACTIMA TM ZD# 52 SYNTAX 52 Elagolix 52 rosuvastatin Crestor 52 Cancer Stem Cells 52 Vandetanib 52 Colorectal Screening 52 metastatic castration resistant 52 Diabetic Retinopathy 52 IMPACT DCM 52 advanced adenomas 52 OVA1 ® 52 GVAX Immunotherapy 52 Lung Cancer Surgery 52 #:#-# [007] 52 Chicago Multidisciplinary Symposium 52 randomized Phase III 52 recurrent NSCLC 52 Silicone Breast Implant 52 GAMMAGARD 52 Bone Metastases 51 MADIT 51 GYTS 51 kidney urologic 51 Benign Prostatic Hyperplasia 51 Phase IIb III 51 Neurological Diseases 51 Non Alcoholic Fatty 51 BZA CE 51 Imaging Technique 51 Levels Linked 51 ductal carcinomas 51 HYVET 51 Elevated Levels 51 journal PNAS Proceedings 51 Breast Tumors 51 Allogeneic 51 ABCSG 51 Sleep Duration 51 #:#-#,# CrossRef Medline [002] 51 Brain Aneurysms 51 Study ARIC 51 florbetaben 51 spiral computed tomography 51 Arimidex Tamoxifen Alone 51 Study Shows Promise 51 Preclinical Models 51 Sorafenib HCC Assessment 51 #:#-# [024] 51 evaluating Actimmune 51 Multicenter Trial 51 metastatic colorectal 51 Chemotherapeutic Agents 51 phase Ib clinical 51 transcranial Doppler ultrasound 51 Dose Ranging Study 51 Clinical Practice Guideline 51 atherothrombotic disease 51 Neurological Disorder 51 Ocular Hypertension Treatment 51 Cardiovascular Risk Factors 51 Breast Cancer Diagnosis 51 Appears Safe 51 Delcath Phase III 51 MANHATTAN KAN 51 Virus Linked 51 Cognitive Decline 51 Insulin Sensitivity 51 COPAXONE R 51 Ovary Removal 51 Rhinosinusitis 51 Catheter Associated 51 Glioma 51 Novel Oral 51 Routine screening 51 Cervical Cancer Screening 51 Radiology Imaging Network ACRIN 51 Endometrial Cancer 51 Fractional Flow Reserve 51 DAPT Study 51 Sniper Suspect Trial 51 Zarnestra 51 Menopausal hormone therapy 51 Postmarketing 51 Schizophrenia Treatment 51 Stroke Risk 51 Breast Cancer Metastasis 51 CONQUER OB 51 renal cell carcinomas 51 Liver Failure 51 Pediatric Diabetes 51 INSPIRE Trial Phase III 51 GRNCM1 51 Radiation Induced 51 confirmatory clinical 51 APEX PD 51 Thyroid Disease 51 Digestive Diseases Week 51 Mesothelioma Treatment 51 Blood Pressure Monitoring 51 Secondhand Smoke Exposure 51 electron beam computed tomography 51 Molecular Basis 51 Paroxysmal Nocturnal Hemoglobinuria PNH 51 CIN2 + 51 Antihypertensive 51 Neoplasia 51 TIMI Study Group 51 Genetic Variants 51 KRAS gene mutations 51 Left Ventricular 51 Chronic Hepatitis C 51 Rheumatoid Arthritis Drug 51 Gene Variants 51 Epratuzumab 51 Cancer Patients Treated 51 Gastrointestinal Oncology 51 CROI 51 Antipsychotic Medications 51 Preterm Delivery 51 Molecular Cancer 51 multicenter Phase II 51 Islet Transplantation 51 Val HeFT 51 IIa Clinical Trial 51 longitudinal observational study 51 NATRECOR R 51 Double Blind Randomized 51 Arteriosclerosis Thrombosis 51 Toxicogenomics 51 Abiraterone Acetate 51 Bone Metabolism 51 asymptomatic carotid stenosis 51 Intravenous CP 51 Polyp Prevention Trial 51 Vascugel ® 51 Framingham Offspring 51 EMPOWER ™ 51 LUMINATE 51 Basal Cell 51 Carcinoid 51 Patient Enrolment 51 Early Diagnosis 51 Zenvia Phase III 51 Symptom Relief 51 transthyretin TTR mediated amyloidosis 51 Gene Variation 51 ICAAC IDSA 51 PET Scanner 51 Nutrition EPIC 51 Protein Expression 51 metastatic androgen independent 51 ug dose 51 NCT# ClinicalTrials.gov 51 secretin 51 Osteoporosis Drug 51 Neuroprotective Effects 51 CARET 51 Enrolling Patients 51 Prognostic Factors 51 deCODE ProstateCancer TM 51 Iressa gefitinib 51 Seconds Count 51 Arthritis Musculoskeletal 51 Beneficial Effects 51 Fabry Disease 51 ARIXTRA 51 tesmilifene 51 Tumor Registry 51 ACTEMRA TM 51 SPORE grant 51 Prednisone Against Refractory 51 Immunotherapeutic 51 Spatio Temporal 51 Liver Cancer 51 Brain Tumors 51 Obese Teens 51 Treatment Naive Patients 51 observational cohort study 51 retrospective cohort 51 Moderate Drinking 51 Brain Atrophy 51 ATTR CM 51 Osteoporotic Fractures 51 Metabolic Endocrinology 51 Detecting Breast Cancer 51 Vaccine Shows Promise 51 longitudinal cohort study 51 Tumor Microenvironment 51 Flavored Cigarettes 51 Curaxin CBLC# 51 Hepatitis C Treatment 51 Uterine Fibroids 51 ILLUSTRATE 51 Racial Ethnic Disparities 51 randomized clinical 51 phase IIa clinical 51 ADVANCE PD 51 ALN HPN 51 FDG PET imaging 51 ALSYMPCA 51 GISSI 51 Prosecution Rests Case 51 miRview ™ squamous 51 Rheumatoid Arthritis Patients 51 Nephropathy 51 Passive Smoking 51 Genetic Tests 51 CARDIA study 51 Cognitive Impairment 51 Breast Cancer Risk 51 Investigational Drugs 51 Therapeutic Approaches 51 Breast Cancer Cells 51 Therapy Evaluation 51 Biological Therapy 51 journal Lancet Neurology 51 Azedra 51 acute PAO 51 Esophageal Cancer 51 FASEB J. 51 Genetic Variation 51 Drug Coated Stents 51 Aplidin R 51 Treating Prostate Cancer 51 Sunesis Pharma 51 Prostate Screenings 51 Arch Intern Med 51 chronic thromboembolic pulmonary 51 Abbott Trilipix 51 Tor Bjerkedal report 51 Transplant Recipient 51 NGFN 51 Home Buyer Seller 51 Adverse Event 51 America HFSA 51 Chronic Myeloid Leukemia 51 pharmacodynamic profiles 51 Combo Therapy 51 Oncotype DX ® 51 Experimental Vaccine 51 Therapeutic Antibody 51 Epidermal Growth Factor Receptor 51 Phase Ib IIa 51 PD2i ® 51 HCV Protease Inhibitor 51 Prostate Disease 51 HealthGrades analyzed 51 Ischemic Heart Disease 51 Randomized controlled 51 pelvic malignancies 51 Osteoporosis Drugs 51 Treatment Regimens 51 Genital Herpes 51 Systolic Hypertension 51 BZL# 50 Genetic Susceptibility 50 Restenosis 50 Diabetic Nephropathy 50 Hsp# Inhibitor 50 multicenter multinational 50 Coronary CTA 50 Relapsing Remitting Multiple Sclerosis 50 Efficacy Results 50 Benign Prostatic Hyperplasia BPH 50 Multivariate logistic regression 50 Acetonide 50 Help Smokers Quit 50 Bowel Project 50 TB Vaccine 50 LHON 50 Initiate Phase 50 Fracture Risk 50 Racial Disparities 50 subgroup analyzes 50 congenital toxoplasmosis 50 Phase IIb Clinical Trial 50 Pivotal Phase 50 Kaplan Meier analysis 50 Maven Semantic 50 HGPIN 50 NEVO RES 50 Magnetic Nanoparticles 50 Statin therapy 50 journal Neuropsychopharmacology 50 Fecal occult blood